AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: inflammatory diseases

newssourceFORcompanycontentinformation1releasesmarket

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi...

AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND

THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for...

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape. 
Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the...

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team

Janet Loesberg, PhRMA/Biotech veteran, brings medical and launch expertise. SUMMIT, N.J., July 28, 2025 /PRNewswire/ -- Vascarta Inc. today announced the addition of Janet Loesberg,...

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants 
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInflammatory diseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers